QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Q32 Bio Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$7.79+0.27 (+3.59%)

Close on Oct 19, 2026

Market cap: $158.47M
P/E (TTM): 3.2
Dividend yield: –

Q32 Bio Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	54	0	-6.65	3.21	34	2.70	1.67	5.32	–
Research & Development	19	48	32	98	93	100	89	48	21
General & Administrative	18	18	9.88	38	37	33	22	17	8.28
Operating Expenses	37	66	42	136	130	133	112	65	30
Operating Income	17	-66	-48	-133	-96	-130	-110	-60	-30
Interest Expense	–	–	1.50	–	–	–	–	–	–
Income from Equity Investments	0	-1.63	0	–	–	–	–	–	–
Other Non-Operating Income	13	20	-5.17	134	0.19	1.57	6.03	4.35	-0.33
Merger & Restructuring Charges	–	–	10	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	–
Gain (Loss) on Sale of Assets	0	0	0	-0.05	-0.13	-0.89	-0.01	-0.13	–
Pretax Income	30	-46	-53	1.20	-96	–	–	–	–
Income Tax Expense	0	0.02	0.32	0.72	0	0	0	0	0
Net Income incl. Noncontrolling Interests	–	–	-113	-5.01	-96	-129	-104	-56	-30
Net Income	30	-48	-54	-5.01	-96	-129	-104	-56	-30
Net Income to Common	0.03	-0.05	-0.05	–	–	–	–	–	–
EPS (Basic)(per share)	2.42	-5.12	-153.96	-14.94	-287.18	-464.80	-410.02	-323.70	-2,008.60
EPS (Diluted)(per share)	2.42	-6.58	-153.96	-14.94	-287.18	-464.80	-410.02	-323.70	-2,008.60
Shares Outstanding (Basic, Weighted)(shares)	12	9.32	0.35	0.35	0.33	0.28	0.25	0.17	0.01
Shares Outstanding (Diluted, Weighted)(shares)	12	9.66	0.35	0.35	0.33	0.28	0.25	0.17	0.01
Net Interest Income	1.06	2.83	0.69	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: 39.9%
Net margin: 62.9%
Return on equity, FY2025: 125.1%

Financial strength

Current ratio: 20.30
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1967.6%

Valuation

P/E ratio: 3.2
Price to sales: 2.95
Price to book: 1.50
Dividend yield: –